MY157886A - Copper (II) -Mixed Ligand Complexes with Anticancer Properties - Google Patents

Copper (II) -Mixed Ligand Complexes with Anticancer Properties

Info

Publication number
MY157886A
MY157886A MYPI2012700421A MYPI2012700421A MY157886A MY 157886 A MY157886 A MY 157886A MY PI2012700421 A MYPI2012700421 A MY PI2012700421A MY PI2012700421 A MYPI2012700421 A MY PI2012700421A MY 157886 A MY157886 A MY 157886A
Authority
MY
Malaysia
Prior art keywords
anticancer properties
copper
complexes
amino acid
series
Prior art date
Application number
MYPI2012700421A
Inventor
Kong Siew Ming
Ng Chew Hee
Munirah Ahmad
Alan Khoo Soo Beng
Original Assignee
Universiti Tunku Abdul Rahman
Inst Medical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiti Tunku Abdul Rahman, Inst Medical Res filed Critical Universiti Tunku Abdul Rahman
Priority to MYPI2012700421A priority Critical patent/MY157886A/en
Priority to PCT/MY2013/000120 priority patent/WO2014003541A1/en
Publication of MY157886A publication Critical patent/MY157886A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

THE PRESENT INVENTION DISCLOSES PHARMACEUTICAL COMPOSITION HAVING AT LEAST ONE OF THE SERIES OF TERNARY COPPER(II) COMPLEXES, [CU(PHEN)(AA)(H2O)]NO3?xH2O FROM 1,10-PHENANTHROLINE AND AMINO ACID LIGANDS. THE SAID AMINO ACID LIGANDS ARE GLYCINE (GLY), SARCOSINE (SAR), DL-ALANINE (DL-aLa), OR 2,2-DIMETHYLGLYCINE (C-dMg). THE SERIES OF TERNARY COPPER(II) COMPLEXES WITH ANTICANCER PROPERTIES ARE FURTHER CHARACTERIZED BY SELECTIVELY TOWARDS CANCER CELLS. THE ANTICANCER PROPERTIES ARE DUE TO INCREASE REACTIVE OXYGEN SPECIES (ROS) GENERATION, SELECTIVE INDUCTION OF NUCLEAR DOUBLE STRAND DNA BREAKS (DSBs), CELL CYCLE ARRESTED AT GO/G1, PROTEASOME INHIBITION, OXIDATIVE DNA DAMAGE AND TOPOISOMERASE I (TOPO I) INHIBITION. MOST ILLUSTRATIVE DIAGRAM:
MYPI2012700421A 2012-06-28 2012-06-28 Copper (II) -Mixed Ligand Complexes with Anticancer Properties MY157886A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MYPI2012700421A MY157886A (en) 2012-06-28 2012-06-28 Copper (II) -Mixed Ligand Complexes with Anticancer Properties
PCT/MY2013/000120 WO2014003541A1 (en) 2012-06-28 2013-06-28 Copper(ii) -mixed ligand complexes with anticancer properties

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI2012700421A MY157886A (en) 2012-06-28 2012-06-28 Copper (II) -Mixed Ligand Complexes with Anticancer Properties

Publications (1)

Publication Number Publication Date
MY157886A true MY157886A (en) 2016-08-04

Family

ID=49783573

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2012700421A MY157886A (en) 2012-06-28 2012-06-28 Copper (II) -Mixed Ligand Complexes with Anticancer Properties

Country Status (2)

Country Link
MY (1) MY157886A (en)
WO (1) WO2014003541A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105440059B (en) * 2014-06-11 2018-06-12 首都师范大学 Copper complex of amino acid and phenanthroline or derivatives thereof and its preparation method and application
WO2016005992A1 (en) * 2014-07-11 2016-01-14 Council Of Scientific And Industrial Research SUBSTITUTED NAPHTHO[2,1-b][1,10]PHENANTHROLINE BASED FLUORESCENT DYES AND APPLICATION THEREOF
CN106883251A (en) * 2017-02-23 2017-06-23 天津市医药科学研究所 A kind of many pyridine copper complexes of amino acid and its preparation method and application

Also Published As

Publication number Publication date
WO2014003541A1 (en) 2014-01-03

Similar Documents

Publication Publication Date Title
WO2014011753A3 (en) Anthraquinone analogs and methods of making and using thereof
WO2010104306A3 (en) Pharmaceutical compositions for treating or preventing diseases caused by the translocation of gsk3 from the cell nucleus to the cytoplasm, containing compounds for inhibiting the translocation of gsk3 from the cell nucleus to the cytoplasm
MX2017004888A (en) Metal complexes of substituted catecholates and redox flow batteries containing the same.
PH12015500268A1 (en) High solubility iron hexacyanides
MX2015017974A (en) Biophotonic compositions comprising a chromophore and a gelling agent for treating wounds.
IN2014MN01724A (en)
WO2013093508A3 (en) Wnt pathway inhibitors
NZ602139A (en) Plant peptide gamma-zein for delivery of biomolecules into plant cells
WO2011034906A3 (en) Recurrent gene fusions in prostate cancer
EA201490067A1 (en) COMPOSITIONS AND METHODS FOR CANCER TREATMENT
MY157886A (en) Copper (II) -Mixed Ligand Complexes with Anticancer Properties
PH12015500183A1 (en) Redox flow batteries comprising matched ionomer membranes
SG11201405866VA (en) Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
WO2010028187A3 (en) Methods and compositions for the treatment of cancer
PH12015500252A1 (en) Niclosamide for the treatment of solid tumors
WO2014039533A3 (en) Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
MX341688B (en) Mixed amino acid metal salt complexes.
EP2551039A4 (en) Complex of organic compound and copper nanoparticles, complex of organic compound and copper oxide (i) nanoparticles, and processes for production of the complexes
MX359210B (en) Procaspase 3 activation by combination therapy.
MY169857A (en) Polymerization-catalyst composition for conjugated-diene monomer
GB201309925D0 (en) Preparation method for caspofungin analog
WO2015081117A3 (en) Therapeutic metal complexes
WO2010110993A3 (en) Methods and compositions for the treatment of cancer
WO2013153450A3 (en) Coriolus versicolor extracts, methods of isolating biologically-active compounds, and uses thereof
MX2018010726A (en) Compositions and methods for inhibiting precipitation of dyes in a beverage.